Takeda America Holdings agreed to pay $140 million to purchase Envoy Therapeutics, a privately held drug discovery firm. The acquisition will give Takeda access to Envoy's pipeline of preclinical central nervous system drugs as well as its proprietary bacTRAP technology, which Takeda says combines "innovative genetic engineering with molecular biology techniques for labeling and extracting the protein-making components of specific types of cells."